Sage Journals: Discover world-class research

Abstract

Objectives

To describe the attitudes and perceptions of postmenopausal women from the United Kingdom regarding menopause, vulvo-vaginal atrophy and its therapeutic management.

Study design

Post hoc analysis of the United Kingdom population from the REVIVE-EU Study.

Main outcome measures

The survey contained questions about women’s knowledge of menopause and vulvo-vaginal atrophy symptoms, impact on their life and sexual activities, communication with healthcare professionals and treatments.

Results

The most frequent symptom of menopause was hot flushes (75%). Vulvo-vaginal atrophy symptoms had a significant impact on participants’ ability to enjoy sexual intercourse (66%), spontaneity (62%) and ability to be intimate (61%); however, only 68% of women had been to their healthcare professional for advice. Half of the sample expected that doctors would initiate a discussion of menopausal symptoms and sexual health, but was in fact rare (5%). Only 27% were under current treatment without a clear therapy pattern, of which 43% used vaginal over-the-counter treatments, 28% prescription (Rx), and 13% both. Efficacy was the main limitation for over-the-counter treatments, while for Rx products were side effects and safety. Women highlighted the restoring of the natural condition of the vagina as the main goal for a treatment (35%). Many United Kingdom women did not feel the need to see any healthcare professional for their gynaecological symptoms. Overall satisfaction with treatment was only 44%.

Conclusions

Vulvo-vaginal atrophy remains underdiagnosed and undertreated in United Kingdom. There is a lack of coherent discussion about vulvo-vaginal atrophy symptoms with clinicians. Many United Kingdom healthcare professionals could improve proactive communication with patients about vulvo-vaginal atrophy.

Keywords

Postmenopausal women REVIVE survey sexual relationships vaginal dryness vulvar and vaginal atrophy

Get full access to this article

View all access options for this article.

References

Mac Bride

Rhodes

Shuster

LT.

Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87–94.

Lachowsky

Nappi

RE.

The effects of oestrogen on urogenital health. Maturitas 2009; 63: 149–151.

Bruce

Rymer

Symptoms of the menopause. Best Pract Res Clin Obst Gynaecol 2009; 23: 25–32.

Santoro

and Komi

Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133–2142.

Nappi

and Lachowsky

Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009; 63: 138–141.

Palacios

Managing urogenital atrophy. Maturitas 2009; 63: 315–318.

Castelo-Branco

Biglia

Nappi

, et al. Characteristics of post-menopausal women with genitourinary syndrome of menopause: implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas 2015; 81: 462–469.

Nappi

Palacios

Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3–9.

DiBonaventura

Luo

Moffatt

, et al. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Womens Health 2015; 24: 713–722.

10.

Parish

Nappi

Krychman

, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437–447.

11.

Palacios

Nappi

Bruyniks

, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018; 21: 286–291.

12.

Kingsberg

Krychman

ML.

Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013; 10: 1567–1574.

13.

North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 355–369; quiz 370–371.

14.

Khanjani

Panay

Vaginal estrogen deficiency. Obstet Gynaecol 2019; 21: 37–42.

15.

Kingsberg

Wysocki

Magnus

, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790–1799.

16.

Nappi

Kokot-Kierepa

Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric 2012; 15: 36–44.

17.

Nappi

and Nijland

EA.

Women’s perception of sexuality around the menopause: outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008; 137: 10–16.

18.

Nappi

Mattsson

L-Å

Lachowsky

, et al. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas 2013; 75: 373–379.

19.

Novo

Data reveal the negative emotional and physical impact that a silent symptom of menopause has on U.S. women and their partners. Press Release, 5 October 2012.

20.

Nappi

Palacios

Panay

, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016; 19: 188–197.

21.

Palacios

Cancelo

Castelo Branco

, et al. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric 2017; 20: 55–61.

22.

Nappi

Particco

Biglia

, et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: evidence from the European REVIVE survey. Maturitas 2016; 91: 74–80.

23.

Nappi

and Krychman

ML.

The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey. Climacteric 2016; 19: 252–255.

24.

Krychman

Graham

Bernick

, et al. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017; 14: 425–433.

25.

Kingsberg

Krychman

Graham

, et al. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med 2017; 14: 413–424.

26.

Coulter

Jenkinson

European patients’ views on the responsiveness of health systems and healthcare providers. Eur J

Pub Health 2005; 15: 355–360.

Symptoms,attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study

Abstract

Objectives

Study design

Main outcome measures

Results

Conclusions

Keywords

Get full access to this article

References